Physician profile

Heidi J Oster

Obstetrics & Gynecology · Lone Tree, CO

NPI 1902863541

$7,870.94

in general payments reported to CMS, 2019-2025

46 companies · $929 in 2025

The $929 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,990.21
Education$99.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $2,395.39 2022-2024 Da Vinci Surgical System
Abbvie INC. $1,028.72 2019-2025
Hologic Sales and Service, LLC $992.59 2019-2025 Acessa Provu System, Novasure, Myosure Tissue Removal Device
Organon LLC $374.44 2021-2025 Nexplanon
Coopersurgical, INC. $272.95 2019-2024 Summit Doppler, Paragard T 380a, Paragard T 380a
Mayne Pharma Commercial LLC $267.57 2021-2025
Bayer Healthcare Pharmaceuticals INC. $239.73 2022-2025
Exeltis, USA INC. $223.23 2020-2025 Slynd
Astellas Pharma US INC $209.96 2023-2025 Veozah
Coloplast Corp $160.75 2024
Medtronic, INC. $137.17 2024 Abre
Myovant Sciences INC. $120.00 2021-2022
Tempus Ai, INC $117.37 2024
Amneal Pharmaceuticals LLC $110.26 2023-2025 Unithroid
Channel Medsystems, INC. $96.06 2022
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $94.32 2022-2025 Pico, Stravix
Therapeuticsmd, INC. $94.00 2019-2022
Avion Pharmaceuticals $81.70 2021-2023 Balcoltra
Exact Sciences Corporation $78.44 2023-2025 Cologuard Collection Kit
Merck Sharp & Dohme LLC $66.55 2020-2024 Gardasil, Gardasil 9
Sumitomo Pharma America, INC. $65.02 2023-2025 Myfembree
Pfizer INC. $59.58 2022-2023
Sage Therapeutics, LLC $49.11 2024-2025 Zurzuvae
Ascend Therapeutics US, LLC $40.99 2019-2021
Minerva Surgical, INC $39.56 2024-2025
C. R. Bard, INC. & Subsidiaries $37.60 2022-2024 Bd Onclarity
Mimedx Group, INC. $37.39 2024
Aspira Women'S Health INC $31.53 2020
Allergan, INC. $27.26 2019-2020
Medicem INC. $26.68 2023
Meditrina $26.45 2021
Roche Diagnostics Corporation $24.89 2021
Becton, Dickinson and Company $23.04 2024 Bd Onclarity
Avanos Medical $22.62 2023 On-Q* Pump and Accessories
Sanofi Pasteur INC. $22.03 2025
Novo Nordisk INC $19.85 2023 Saxenda, Wegovy
Ibsa Pharma INC. $18.81 2025 Tirosint, Licart, Flector
Lupin INC. $18.67 2021
Currax Pharmaceuticals LLC $17.54 2025 Contrave
Shield Therapeutics INC $16.26 2024
Idorsia Pharmaceuticals US INC $15.82 2024 Quviviq
Lsi Solutions INC $15.54 2025 Fornisee
Gynesonics, INC. $14.56 2022
Innovation Technologies INC $13.81 2025 Irrisept
Teleflex LLC $13.43 2022
Dysis Medical, INC. $11.70 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Heidi J Oster

$7,870.94

in general payments reported 2019-2025

Years
2019-2025
Top company
Intuitive Surgical, INC.
Context
The $929 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).

https://glasscript.com/doctor/1129358/heidi-j-oster

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.